

Melissa J Nirenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9044739/publications.pdf>

Version: 2024-02-01

37
papers

2,604
citations

393982

19
h-index

433756

31
g-index

37
all docs

37
docs citations

37
times ranked

2859
citing authors

#	ARTICLE	IF	CITATIONS
1	The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. <i>Journal of Neuroscience</i> , 1996, 16, 436-447.	1.7	430
2	Dopamine Agonist Withdrawal Syndrome in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 58-63.	4.9	299
3	Compulsive eating and weight gain related to dopamine agonist use. <i>Movement Disorders</i> , 2006, 21, 524-529.	2.2	239
4	Ultrastructural Localization of the Vesicular Monoamine Transporter-2 in Midbrain Dopaminergic Neurons: Potential Sites for Somatodendritic Storage and Release of Dopamine. <i>Journal of Neuroscience</i> , 1996, 16, 4135-4145.	1.7	212
5	iPSC-Derived Dopamine Neurons Reveal Differences between Monozygotic Twins Discordant for Parkinson's Disease. <i>Cell Reports</i> , 2014, 9, 1173-1182.	2.9	202
6	The Dopamine Transporter: Comparative Ultrastructure of Dopaminergic Axons in Limbic and Motor Compartments of the Nucleus Accumbens. <i>Journal of Neuroscience</i> , 1997, 17, 6899-6907.	1.7	185
7	Prospective cohort study of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 327-333.	2.2	136
8	Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care. <i>Drugs and Aging</i> , 2013, 30, 587-592.	1.3	110
9	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , 2015, 30, 150-159.	2.2	92
10	Impulse Control and Related Disorders in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2013, 11, 63-71.	0.8	82
11	Ultrastructural view of central catecholaminergic transmission: immunocytochemical localization of synthesizing enzymes, transporters and receptors. <i>Journal of Neurocytology</i> , 1996, 25, 843-856.	1.6	77
12	Vesicular monoamine transporter-2: Immunogold localization in striatal axons and terminals. , 1997, 26, 194-198.		74
13	Multinuclear Magnetic Resonance Spectroscopy for <i>in Vivo</i> Assessment of Mitochondrial Dysfunction in Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , 2008, 1147, 206-220.	1.8	67
14	Immunogold Localization of the Dopamine Transporter: An Ultrastructural Study of the Rat Ventral Tegmental Area. <i>Journal of Neuroscience</i> , 1997, 17, 4037-4044.	1.7	49
15	Clinical Characteristics of Exacerbations in Parkinson Disease. <i>Neurologist</i> , 2012, 18, 120-124.	0.4	43
16	Region-specific targeting of dopamine D2-receptors and somatodendritic vesicular monoamine transporter 2 (VMAT2) within ventral tegmental area subdivisions. <i>Synapse</i> , 2002, 45, 113-124.	0.6	41
17	Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutation. <i>Movement Disorders</i> , 2007, 22, 251-253.	2.2	38
18	Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 40-45.	1.1	28

#	ARTICLE	IF	CITATIONS
19	Immunocytochemical localization of the renal neutral and basic amino acid transporter in rat adrenal gland, brainstem, and spinal cord. <i>Journal of Comparative Neurology</i> , 1995, 356, 505-522.	0.9	21
20	Sex differences in cerebral energy metabolism in Parkinson's disease: A phosphorus magnetic resonance spectroscopic imaging study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 545-548.	1.1	20
21	Clinical predictors of frequent patient telephone calls in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 95-99.	1.1	19
22	A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 170-174.	0.8	19
23	An MDS Evidence-Based Review on Treatments for Huntington's Disease. <i>Movement Disorders</i> , 2022, 37, 25-35.	2.2	19
24	Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery. <i>Brain</i> , 2010, 133, e155-e155.	3.7	16
25	A novel TRPA1 variant is associated with carbamazepine-responsive cramp-fasciculation syndrome. <i>Clinical Genetics</i> , 2018, 93, 164-168.	1.0	16
26	Regional and subcellular distribution of a neutral and basic amino acid transporter in forebrain neurons containing nitric oxide synthase. , 1999, 404, 459-472.		15
27	Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 269-270.	1.1	15
28	Nocturnal eating in restless legs syndrome. <i>Movement Disorders</i> , 2010, 25, 126-127.	2.2	9
29	Longitudinally Extensive Nitrous Oxide Myelopathy With Novel Radiographic Features. <i>JAMA Neurology</i> , 2015, 72, 1370.	4.5	9
30	Myoclonus. <i>Current Treatment Options in Neurology</i> , 2005, 7, 221-230.	0.7	8
31	Carbidopa/levodopa pharmacy errors in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2867-2871.	2.2	6
32	New-Onset Movement Disorders in COVID-19: Much Ado about Nothing?. <i>Tremor and Other Hyperkinetic Movements</i> , 2021, 11, 31.	1.1	4
33	Catecholamines, Opioids, and Vagal Afferents in the Nucleus of the Solitary Tract. <i>Advances in Pharmacology</i> , 1997, 42, 642-645.	1.2	3
34	Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?. <i>Neurology</i> , 2016, 87, 2603-2603.	1.5	1
35	Fragile X Tremor Ataxia Syndrome With Rapidly Progressive Myopathy. <i>JAMA Neurology</i> , 2015, 72, 946.	4.5	0
36	Letter re: The terrorist inside my husband's brain. <i>Neurology</i> , 2017, 88, 1104-1104.	1.5	0

#	ARTICLE	IF	CITATIONS
37	Treatment of Impulse Control Disorders and Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. Current Clinical Neurology, 2019, , 121-123.	0.1	0